BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by StockNews.com

BioCryst Pharmaceuticals (NASDAQ:BCRX) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Tuesday.

BCRX has been the topic of several other research reports. Needham & Company LLC restated a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $14.17.

BioCryst Pharmaceuticals Stock Up 4.8 %

BioCryst Pharmaceuticals stock traded up $0.36 during mid-day trading on Tuesday, hitting $7.87. The company’s stock had a trading volume of 3,848,845 shares, compared to its average volume of 3,410,858. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $7.93. The stock’s fifty day moving average price is $6.75 and its two-hundred day moving average price is $5.79. The stock has a market capitalization of $1.62 billion, a P/E ratio of -7.36 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.11. The company had revenue of $109.30 million during the quarter, compared to analyst estimates of $98.30 million. The business’s revenue was up 34.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. Equities analysts expect that BioCryst Pharmaceuticals will post -0.65 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Amy E. Mckee sold 8,600 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $6.32, for a total transaction of $54,352.00. Following the completion of the sale, the director now owns 27,831 shares of the company’s stock, valued at $175,891.92. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other BioCryst Pharmaceuticals news, Director Amy E. Mckee sold 8,600 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $6.32, for a total value of $54,352.00. Following the transaction, the director now directly owns 27,831 shares of the company’s stock, valued at approximately $175,891.92. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Machelle Sanders sold 4,689 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $6.00, for a total value of $28,134.00. Following the sale, the director now owns 27,742 shares of the company’s stock, valued at $166,452. The disclosure for this sale can be found here. Insiders purchased a total of 103,601 shares of company stock worth $596,338 in the last quarter. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently added to or reduced their stakes in BCRX. CWM LLC raised its holdings in shares of BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,772 shares in the last quarter. Diversified Trust Co raised its holdings in BioCryst Pharmaceuticals by 18.0% during the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 3,774 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of BioCryst Pharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock worth $246,000 after buying an additional 4,041 shares during the last quarter. Signaturefd LLC boosted its stake in shares of BioCryst Pharmaceuticals by 560.5% during the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,599 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of BioCryst Pharmaceuticals by 131.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 5,912 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.